

# Yue Che, MD

Associate professor

University Hospital of Duesseldorf

Heinrich-Heine-University of Duesseldorf, Germany

40225 Düsseldorf, Germany

Phone: +49 (0) 211-81-04938

Fax: +49 (0) 211-81-18676

E-Mail: [yue.che@med.uni-duesseldorf.de](mailto:yue.che@med.uni-duesseldorf.de)

## Personal data

|              |                                       |
|--------------|---------------------------------------|
| Name         | Dr. med. Yue Che                      |
| Born         | December 25, 1986 in Hefei / China    |
| Nationality  | German                                |
| Civil status | Married, three children               |
| Address      | Rüdelstr. 10, 50737, Cologne, Germany |

## Education / training

|                   |  |
|-------------------|--|
| 09/1993 – 06/2005 | High School at Deutsche Schule Las Palmas / Spain  |
| 2005 – 2011       | Medical School, University of Freiburg im Breisgau   |
| 2012              | Assistant at the Dean's office of the Faculty of Medicine, Freiburg im Breisgau  |
| 04/2015           | M.D. "The functional integration of voxel-based morphometry changes after mirror therapy", Department of Neurology, University of Freiburg im Breisgau |
| 2012 – 2015       | Residency in General Surgery at KH Porz am Rhein   |
| 2015 – 2018       | Residency in Urology at Heilig Geist KH Cologne  |
| 2019 – present    | Urologist at University Hospital of Duesseldorf  |

## Scientific Career

|                   |  |
|-------------------|--|
| 11/2007 – 06/2010 | Scientific assistant "handsearcher" at German Cochrane Centre (Freiburg)                   |
| 2019 – present    | Testis cancer research team of Duesseldorf   |
| From 2022         | Lead of Expertise Area Testicular Cancer and Coordinator of HCP Duesseldorf<br>ERN eUROGEN |

## Biographical sketch

Yue Che is a clinical scientist and urologist at the Department of Urology, Heinrich-Heine-University Düsseldorf, Germany, specializing in open and robotic retroperitoneal surgery with a focus on testicular cancer. He received his medical degree from the University of Freiburg and began his surgical residency at the Porz am Rhein Hospital in 2012. In 2015, he successfully defended his PhD thesis entitled "The functional integration of voxel-based morphometric changes after mirror therapy". From 2015 to 2018, he completed his urology residency at the Heilig Geist Hospital in Cologne, Germany. Afterwards, Dr. Che started working as a urologist at the University Hospital of Düsseldorf and was appointed as a senior physician in 2020. Since 2019, he has been a member of the clinical research team for testicular cancer in Düsseldorf and has been appointed head of this team in 2022.

## Publications

### Scientific articles

**Che Y**, Lusch A, Winter C, Große Siemer R, Buddensieck C, Albers P, Hiester A. Late relapsing germ cell tumors with elevated tumor markers. *World J Urol.* 2022 Feb;40(2):363-371. doi: 10.1007/s00345-021-03833-z. Epub 2021 Sep 13. PMID: 34518930; PMCID: PMC8921136.

**Che Y**, Buddensieck C, Albers P, Lusch A, Winter C, Siemer RG, Hiester A. Postchemotherapy Residual Tumor Resection in Patients with Elevated Tumor Markers. *J Urol.* 2022 Mar;207(3):617-626. doi: 10.1097/JU.0000000000002270. Epub 2021 Oct 25. PMID: 34694152.

Hiester A\*, **Che Y\***, Lusch A, Kuß O, Niegisch G, Lorch A, Arsov C, Albers P. Phase 2 Single-arm Trial of Primary Retroperitoneal Lymph Node Dissection in Patients with Seminomatous Testicular Germ Cell Tumors with Clinical Stage IIA/B (PRIMETEST). *Eur Urol.* 2023 Jul;84(1):25-31. doi: 10.1016/j.eururo.2022.10.021. Epub 2022 Nov 10. PMID: 36372627. \*These authors contributed equally

Majewski M, Paffenholz P, Ruf C, **Che Y**, Seidel C, Heinzlbecker J, Schmelz HU, Matthies C, Albers P, Bokemeyer C, Heidenreich A, Pichler M, Nestler T; GTCSG (German Testicular Cancer Study Group). Misuse of tumor marker levels leads to an insufficient International Germ Cell Consensus Classification (IGCCCG) risk group assignment and impaired treatment. *Cancer Med.* 2023 Aug;12(16):16829-16836. doi: 10.1002/cam4.6304. Epub 2023 Jul 1. PMID: 37392170; PMCID: PMC10501278.

Rehlinghaus M, Rehker P, **Che Y**, Grunewald CM, Niegisch G. Neutropenie – wann ist eine GCSF Unterstützung notwendig? [Neutropenia - when is GCSF support indicated?]. *Aktuelle Urol.* 2024 Feb;55(1):38-43. German. doi: 10.1055/a-2128-4965. Epub 2023 Aug 22. PMID: 37607583.

Bremmer F, Pongratanakul P, Skowron M, **Che Y**, Richter A, Küffer S, Reuter-Jessen K, Bohnenberger H, Pauls S, Kresbach C, Schüller U, Stühler K, Ströbel P, Albers P, Nettersheim D. Characterizing the mutational burden, DNA methylation landscape, and proteome of germ cell tumor-related somatic-type malignancies to identify the tissue-of-origin, mechanisms of therapy resistance, and druggable targets. *Br J Cancer*. 2023 Nov;129(10):1580-1589. doi: 10.1038/s41416-023-02425-5. Epub 2023 Sep 19. PMID: 37726478; PMCID: PMC10645790.

Belge G, Dumlupinar C, Nestler T, Klemke M, Törzsök P, Trenti E, Pichler R, Loidl W, **Che Y**, Hiester A, Matthies C, Pichler M, Paffenholz P, Kluth L, Wenzel M, Sommer J, Heinzelbecker J, Schriefer P, Winter A, Zengerling F, Kramer MW, Lengert M, Frey J, Heidenreich A, Wülfing C, Radtke A, Dieckmann KP. Detection of Recurrence through microRNA-371a-3p Serum Levels in a Follow-up of Stage I Testicular Germ Cell Tumors in the DRKS-00019223 Study. *Clin Cancer Res*. 2024 Jan 17;30(2):404-412. doi: 10.1158/1078-0432.CCR-23-0730. PMID: 37967143; PMCID: PMC10792362.

Pongratanakul P, Bremmer F, Pauls S, Poschmann G, Kresbach C, Parmaksiz F, Skowron MA, Fuß J, Stephan A, Paffenholz P, Stühler K, Schüller U, Ströbel P, Heidenreich A, **Che Y**, Albers P, Nettersheim D. Assessing the risk to develop a growing teratoma syndrome based on molecular and epigenetic subtyping as well as novel secreted biomarkers. *Cancer Lett*. 2024 Mar 31;585:216673. doi: 10.1016/j.canlet.2024.216673. Epub 2024 Jan 29. PMID: 38296184.

Dieckmann KP, Grobelny F, Soave A, **Che Y**, Nestler T, Matthies C, Heinzelbecker J, Winter A, Heidenreich A, Niemzok T, Dumlupinar C, Angerer M, Wülfing C, Paffenholz P, Belge G. Serum Levels of MicroRNA-371a-3p for Predicting the Histology of Postchemotherapy Residual Masses of Germ Cell Tumours. *Eur Urol Focus*. 2024 May 9:S2405-4569(24)00064-6. doi: 10.1016/j.euf.2024.05.002. Epub ahead of print. PMID: 38729824.

Stephan A, Suhrmann JH, Skowron MA, **Che Y**, Poschmann G, Petzsch P, Kresbach C, Wruck W, Pongratanakul P, Adjaye J, Stühler K, Köhrer K, Schüller U, Nettersheim D. Molecular and epigenetic ex vivo profiling of testis cancer-associated fibroblasts and their interaction with germ cell tumor cells and macrophages. *Matrix Biol*. 2024 Jun 6:S0945-053X(24)00077-5. doi: 10.1016/j.matbio.2024.06.001. Epub ahead of print. PMID: 38851302.

Vermeulen-Spohn MS, Pongratanakul P, Thy S, Dukart J, Albers P, **Che Y**, RAISN: Robot-assisted Indocyanine Green-guided Sentinel Node Biopsy in Clinical Stage I Germ Cell Tumor, *Eur Urol Open Science*, Volume 66, 2024 Aug, Pages 55-59, ISSN 2666-1683, <https://doi.org/10.1016/j.euros.2024.06.004>.

## Books

Rare and Complex Urology. 2024. Chapter 23 – Testicular cancer. Arnout Alberts, Tomas Buchler, **Yue Che**, Ana Fröbe, Marija Miletić, Tahlita Zuiverloon